<DOC>
	<DOCNO>NCT01436539</DOCNO>
	<brief_summary>The purpose study evaluate effect safety Adefovir Dipivoxil plus polyene phosphatidylcholine compare Adefovir Dipivoxil alone patient chronic hepatitis B .</brief_summary>
	<brief_title>Study Effects Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone Chronic Hepatitis B Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Polyene phosphatidylcholine</mesh_term>
	<criteria>Males female age 18 65 year chronic hepatitis B. HBsAg positive minimum 6 month . HBV DNA ≥4 log10 copies/ml , ≤ 6 log10 copies/mL Alanine aminotransferase ( ALT ) ≥ 2 time upper limit normal ( ULN ) ≤10 time ULN , document ALT abnormal within 6 month prior study screening . Had liver biopsy perform within 6 month prior randomization readable biopsy slide agree biopsy perform prior entry . Willing able provide write informed consent . Received nucleoside , nucleotide interferon therapy within 6 month prior screen . Previous treatment lamivudine , adefovir , entecavir telbivudine occur viral breakthrough genotype resistance . Received immunosuppressive agent immunoregulates ( include thymosin ) , systemic cytotoxic drug , antiviral agent include Chinese herb medicine within 6 month prior screen . Active alcohol intake ( 20g/d female 30g/d male ) drug abuse within 1 year prior screen . Alcohol drug abuse consider investigator sufficient hinder compliance treatment , participation study interpretation result . ALT great 10 time ULN screen history transient decompensated liver disease due acute exacerbation . Any laboratory test screen follow : serum creatinine &gt; 1.5 mg/dl ; prothrombin time ≥ 4 second prolonged PTA &lt; 60 % ; serum albumin &lt; 32 g/L ; serum bilirubin &gt; 3.0mg/dL ; Hemoglobin &lt; 11g/dL ( male ) &lt; 10 g/dL ( female ) , white blood cell count &lt; 3.5 x 10^9/L , absolute neutrophil count &lt; 1.5 x 10^9/L , platelet &lt; 80 x 10^9/L . Patient coinfected HCV , HDV HIV . Hepatocellular carcinoma ( HCC ) , presence mass image study liver suggest HCC , alphafetoprotein ( AFP ) &gt; 500ng/mL . Decompensated liver disease define serum bilirubin &gt; 3mg/dL , prothrombin time≥ 4 second prolonged , serum albumin &lt; 32g/L , history ascites , variceal bleed hepatic encephalopathy . Presence cause liver disease ( i.e.alcoholic liver disease , autoimmune hepatitis , hemochromatosis , Wilson disease , nonalcoholic steatohepatitis , alpha1antitrypsin deficiency ) . Any serious active medical psychiatric illness hepatitis B , opinion investigator , would interfere patient treatment , assessment compliance protocol . This would include , may limit , renal , cardiac , pulmonary , vascular , neurogenic , digestive , metabolic ( diabetes , thyroid disorder , adrenal disease ) , immunodeficiency disorder , active infection cancer . BMI≥30 . Patient pregnant breastfeeding . Planned liver transplantation previous liver transplantation . Need take hepatotoxic drug ( e.g. , dapsone , erythromycin , fluconazole , rifampin , etc ) nephrotoxic drug ( e.g. , NSAIDs , aminoglycosides , amphotericin B , foscarnet , etc . ) long time . History hypersensitivity nucleoside analogue . Previous ( plan ) participation investigational trial involve administration investigational compound within 12 week prior study screen . Poor compliance patient consider investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>